Association of time in range with metabolic associated fatty liver disease and liver fibrosis in patients with type 2 diabetes
10.3760/cma.j.cn311282-20230326-00136
- VernacularTitle:2型糖尿病患者血糖目标范围内时间与代谢相关脂肪性肝病及肝纤维化的相关性研究
- Author:
Danyu WANG
1
;
Kaikun LIU
;
Xinru DENG
;
Xiaoyang SHI
;
Junpeng YANG
;
Na XU
;
Yaonan CHEN
;
Huijuan YUAN
Author Information
1. 河南省人民医院（郑州大学人民医院）内分泌科，郑州 450003
- Keywords:
Time in range;
Metabolic associated fatty liver disease;
Advanced liver fibrosis
- From:
Chinese Journal of Endocrinology and Metabolism
2024;40(3):198-203
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the association of time in range with metabolic associated fatty liver disease(MAFLD) and advanced liver fibrosis in patients with type 2 diabetes.Methods:This study was a retrospective study. A total of 494 type 2 diabetic patients were recruited in the Department of Endocrinololgy of Henan Provincial People′s Hospital from November 2019 to April 2022. Time in range(TIR) was calculated with continuous glucose monitoring data. Abdominal ultrasound scan was used to diagnose fatty liver. Liver stiffness measurement(LSM) by transient elastography was used to evaluate liver fibrosis. Pearson and multivariate linear regression analysis was used to evaluate the association between TIR and LSM. Multivariate logistic regression analysis was used to analyze the association of TIR with risk of MAFLD and advanced liver fibrosis.Results:Pearson correlation analysis showed that LSM was negatively correlated with TIR( r=-0.86, P<0.001) and was positively correlated with homeostasis model assessment for insulin resistance(HOMA-IR; r=0.48, P<0.001). After adjusting for confounding factors, multivariate linear regression analysis showed that TIR significantly negatively predicted LSM( β=-0.75, P<0.001), and HOMA-IR significantly positively predicted LSM( β=0.21, P=0.025). After adjusting for confounding factors, logistic regression analysis showed that compared with TIR Q4 patients, TIR Q1 patients had an increased risk of MAFLD( OR=1.96, 95% CI 1.07-3.62, P=0.027), advanced liver fibrosis( OR=3.82, 95% CI 1.17-12.50, P=0.027), and HOMA-IR was an independent risk factor for MAFLD( OR=1.22, 95% CI 1.04-1.43, P=0.005) and advanced liver fibrosis( OR=1.26, 95% CI 1.03-1.54, P=0.025). Conclusions:TIR and insulin resistance are independent risk factors for MAFLD and advanced liver fibrosis in patients with type 2 diabetes. TIR has a significant predictive value for MAFLD and advanced liver fibrosis.
